Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11,922 Mln
Revenue (TTM)
$4,715 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.9
Industry P/E
--
EV/EBITDA
23.6
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$13.2
EPS
$-0.5
Face value
--
Shares outstanding
497,168,077
CFO
$2,212.70 Mln
EBITDA
$6,210.30 Mln
Net Profit
$-2,752.10 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Elanco Animal Health (ELAN)
| 10.0 | 0.6 | 12.1 | 136.5 | 41.5 | -2.7 | -- |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Elanco Animal Health (ELAN)
| 86.9 | -18.6 | 21.9 | -56.9 | -7.5 | 4.1 | -6.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Elanco Animal Health (ELAN)
|
24.9 | 11,922.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.9 |
| 11.3 | 3,410.4 | 510.2 | 146.9 | 37.2 | 35.6 | 23.9 | 7.2 | |
| 12.1 | 3,722.1 | 3,018.8 | 72.1 | 12.6 | -80 | 53.8 | 86.1 | |
| 158.8 | 8,027.0 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.0 | |
| 68.5 | 13,287.4 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 33.8 | 3,684.8 | 761.4 | 99.7 | 7.3 | 15 | 42.2 | 5.7 | |
| 13.5 | 11,772.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 19.6 | 3.0 | |
| 7.6 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 201.7 | 4,084.1 | 268.1 | 124.5 | 60.0 | 13.5 | 33.5 | 4.0 | |
| 35.2 | 3,208.3 | 158.3 | -68.9 | -29.3 | -113 | -- | 71.7 |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that... protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana. Read more
President, CEO & Director
Mr. Jeffrey N. Simmons
President, CEO & Director
Mr. Jeffrey N. Simmons
Headquarters
Indianapolis, IN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Elanco Animal Health (ELAN) is $24.90 (NYSE) as of 24-Mar-2026 16:25 EDT. Elanco Animal Health (ELAN) has given a return of 41.49% in the last 3 years.
Since, TTM earnings of Elanco Animal Health (ELAN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-48.47
|
1.72
|
|
2024
|
17.71
|
0.98
|
|
2023
|
-5.96
|
1.18
|
|
2022
|
-76.53
|
0.82
|
|
2021
|
-28.64
|
1.84
|
The 52-week high and low of Elanco Animal Health (ELAN) are Rs 27.72 and Rs 8.02 as of 25-Mar-2026.
Elanco Animal Health (ELAN) has a market capitalisation of $ 11,922 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Elanco Animal Health (ELAN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.46
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.